What to Expect on Your First Day of Wegovy

The 0.25 mg starting dose is a tolerability step: its job is to settle your system, not to drive significant weight loss in week one.
Nausea is the most commonly reported first-day symptom, it is usually mild, peaks a few hours after injection, and often fades within a day or two.
You inject once weekly, on the same day each week; the injection site (abdomen, thigh or upper arm) should be rotated to reduce local reactions.
Wegovy must be stored in the fridge between 2–8 °C before first use; always read the Patient Information Leaflet supplied with your pen for the exact out-of-fridge window.

Your first day of Wegovy starts with a 0.25 mg injection, a dose chosen not because it does much for weight loss but because it gives your body time to adjust to semaglutide without overwhelming it. Clinical trials showed that beginning at this level and titrating slowly reduced the rate of side effects that cause people to stop early. Most people feel something — mild nausea is common — but the majority of first-day experiences are quieter than the internet suggests. Wegovy is a prescription-only medicine, so you'll have already been assessed by a prescriber before you reach this point; the pen in your hand is the result of a clinical decision made about you specifically.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence and official guidance say about starting Wegovy, and what that means in practice on day one

What the STEP 1 trial tells us about the early weeks

The pivotal trial behind Wegovy's UK licence, STEP 1, published in the New England Journal of Medicine, ran 68 weeks and found an average weight loss of around 15 % at the 2.4 mg maintenance dose. That figure comes after a 16-week escalation period during which participants were on lower doses, including the 0.25 mg level where you begin on your first shot of Wegovy. Knowing that tells you something useful: the first few weeks are not where the clinical results were made. They are the foundation.

Gastrointestinal effects were the most frequently reported events in the trial. Nausea affected a substantial proportion of participants, particularly in the early titration phase, and was described as mild to moderate in the majority of cases. This is consistent with what the NHS's semaglutide medicines page describes: nausea, vomiting, diarrhoea and constipation are common, especially around dose changes, and tend to settle as the body adapts. Knowing that the discomfort typically follows a pattern (peaking in the hours after injection and often easing before the next dose) makes it considerably less alarming when it arrives.

If you've been reading about starting semaglutide for the first time and feel a mix of nervousness and cautious optimism, that's an entirely reasonable place to be. The medicine has a robust evidence base, but it is still a new experience for your body.

The practicalities of injecting on day one

Wegovy comes as a pre-filled pen. You do not need to draw up a dose or handle a vial. After washing your hands, choose a clean patch of skin (the abdomen (avoiding a 5 cm radius around the navel), the front of the thigh, or the upper arm) and follow the instructions in your Patient Information Leaflet step by step. The needle is fine and short; most people report that the injection itself is far less noticeable than they expected.

Timing is flexible. You can inject at any point during the day, with or without food. Picking a consistent time on the same day each week helps build the habit. Some people prefer a weekend morning when they can rest if nausea arrives; others find a weekday routine easier to maintain. There is no clinically superior moment, this is entirely about what you will actually do reliably.

If you'd like a broader picture of how to approach using Wegovy for the first time, our treatment overview covers the process from prescription to first dose in more detail. For questions about cost or what a private prescription includes, the Wegovy treatment page sets out what is involved.

Side effects on the first day: what's normal, what warrants attention

Mild nausea in the hours after your first injection is the most common experience. It usually arrives within two to four hours, plateaus, then fades, often gone by the following morning. Eating a small, low-fat meal before injecting and drinking water steadily through the day can help. Fatty or very rich food tends to worsen nausea on semaglutide, so your first injection day is not the occasion for a celebratory takeaway.

Headache, fatigue, and a general sense of digestive sluggishness are also reported, particularly in the first 24 hours. These are consistent with what early experiences on semaglutide commonly look like across the evidence base, and they generally resolve without intervention.

Some symptoms do require prompt medical attention: severe and persistent stomach pain that radiates to the back may signal pancreatitis, which the MHRA has highlighted as a known but infrequent risk with GLP-1 medicines. Signs of a serious allergic reaction, including swelling of the face or throat and difficulty breathing, also require immediate help. These events are rare, but they are the ones worth knowing about before day one, not after. If you have any concerns about side effects once you're on treatment, our clinical team is available seven days a week.

What does not happen on day one

Appetite suppression is real, but it builds gradually with timelapse. On your first day of Wegovy, don't expect to feel dramatically less hungry, that effect tends to become noticeable over several weeks, and more pronounced as the dose increases. Weight loss is similarly a medium-term picture; the 15 % average reduction in STEP 1 took 68 weeks to accumulate.

You also will not know on day one whether this medicine suits you long term. That assessment belongs to a prescriber, and at a regulated service it happens at every repeat review, not just at the start. If you're considering whether Wegovy or another weight-loss treatment is right for your situation, a clinical consultation is where that conversation properly begins. Our prescribers are not gatekeepers; they are the people who make the medicine safe to use.

For a fuller picture of semaglutide and how it works, including how it compares to other licensed options, the semaglutide overview is worth reading before or after your first injection. And if you want to understand what the Wegovy programme involves beyond week one, that page covers the titration journey through to maintenance dose.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions